Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab of its kind in the UK.

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

Led by ex-Arm VP Noel Hurley, Literal Labs uses logic-based techniques to generate AI models that are orders of magnitude ...